Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

SAP fixed the issue in late April 2025, but at the time, multiple security firms were already seeing attacks in the wild.

Sarepta Therapeutics said it will voluntarily “and temporarily” pause all shipments of Elevidys® (delandistrogene ...

Sarepta will soon resume shipping Elevidys for ambulatory Duchenne muscular dystrophy patients after a review of safety data ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: ...

The FDA asked Sarepta to pause all U.S. shipments of the DMD gene therapy Elevidys, and the company has agreed after initially refusing.

CyberArk (CYBR) is a $19 billion provider of cybersecurity solutions to more than 5,400 global businesses, including over half of the Fortune 500 and over 35% of Global 2000 companies. CYBR ...